Repeated low-dose of erythropoietin is associated with improved left ventricular function in rat acute myocardial infarction model
To evaluate the potential protective affects of Epo on left ventricular (LV) function and remodeling after acute myocardial infarction (MI). Epo was injected into the peritoneum of male Wistar rats (250 g) during 6 weeks post induction of MI. Rats were divided into five groups: MI treated with singl...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular drugs and therapy 2007-10, Vol.21 (5), p.339-346 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 346 |
|---|---|
| container_issue | 5 |
| container_start_page | 339 |
| container_title | Cardiovascular drugs and therapy |
| container_volume | 21 |
| creator | BEN-DOR, Itsik HARDY, Britta HARELL, Daniela OKON, Elimelech BATTLER, Alexander HAIM, Moti FUCHS, Shmuel KAGANOVSKY, Ella KADMON, Ehud SAGIE, Alex COLEMAN, Raymond MANSUR, Mali POLITI, Boaz FRASER, Abigail |
| description | To evaluate the potential protective affects of Epo on left ventricular (LV) function and remodeling after acute myocardial infarction (MI).
Epo was injected into the peritoneum of male Wistar rats (250 g) during 6 weeks post induction of MI. Rats were divided into five groups: MI treated with single high dose (MT1, 5,000 U/kg, n=10), single high dose (5,000 U/kg) and repeated high doses (MTHi, 1,000 U/kg twice a week; n=8), or single high dose (5,000 U/kg) and repeated low doses (MTLo, 750 U/kg once a week, n=10), MI non-treated (MNT, n=10), sham (S, n=5). Echocardiography was performed 3.6+/-1.5 days and 43.7+/-2.3 days post MI. Collagen deposition and infarct size were measured on histological sections using computerized image analysis. Apoptosis was assessed by ApopTag staining.
Baseline fractional shortening (FS) was similar between groups. Six weeks after MI the FS of MTLo (26.9%) was significantly higher compared to MNT (17.8%), MT1 (19.5%) and MTH (22.3%) (p=0.01). However, remodeling indices (end diastolic and end systolic areas, LV circumference) did not improve in the Epo groups, and even worsened in the MTHi group. There was significantly less collagen staining in non-infarct areas in MT1 and MTHi groups compared to MNT and MTLo (0.38+/-0.3%, 0.49+/-0.34%, vs 0.89+/-0.41%, 0.95+/-0.33%, respectively, p |
| doi_str_mv | 10.1007/s10557-007-6049-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68546247</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68546247</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-b380be453417d52e3e25b801e4a542544e78a515514bbca441beb59b763ec1253</originalsourceid><addsrcrecordid>eNpd0cuKFDEUBuAgitOOPoAbCYLuorkntZRhvMCAILoOSeoUk6Gq0iapGXrrk5u2GwZc5RC-_3DgR-g1ox8YpeZjZVQpQ_pINJUDsU_QjikjiOGSPUU7OnBKBKf6Ar2o9Y52OAz2ObpgZmBcc75Df37AHnyDEc_5gYy5As4ThnJotyXvc4KWVpwq9rXmmP7Bh9RucVr2Jd8fYzA1fA9rKylusy942tbYUu6pFRffsI9bA7wccvRlTH7u_5MvJ7LkEeaX6Nnk5wqvzu8l-vX5-ufVV3Lz_cu3q083JAqlGwnC0gBSCcnMqDgI4CpYykB6JbmSEoz1iinFZAjRS8kCBDUEowVExpW4RO9Pe_vlvzeozS2pRphnv0LeqtNWSc2l6fDtf_Aub2XttznOhJWWad4RO6FYcq0FJrcvafHl4Bh1x3bcqR13HI_tONszb86Lt7DA-Jg419HBuzPwNfp5Kn6NqT66gXNmqRZ_ATfamTc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213848162</pqid></control><display><type>article</type><title>Repeated low-dose of erythropoietin is associated with improved left ventricular function in rat acute myocardial infarction model</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>BEN-DOR, Itsik ; HARDY, Britta ; HARELL, Daniela ; OKON, Elimelech ; BATTLER, Alexander ; HAIM, Moti ; FUCHS, Shmuel ; KAGANOVSKY, Ella ; KADMON, Ehud ; SAGIE, Alex ; COLEMAN, Raymond ; MANSUR, Mali ; POLITI, Boaz ; FRASER, Abigail</creator><creatorcontrib>BEN-DOR, Itsik ; HARDY, Britta ; HARELL, Daniela ; OKON, Elimelech ; BATTLER, Alexander ; HAIM, Moti ; FUCHS, Shmuel ; KAGANOVSKY, Ella ; KADMON, Ehud ; SAGIE, Alex ; COLEMAN, Raymond ; MANSUR, Mali ; POLITI, Boaz ; FRASER, Abigail</creatorcontrib><description>To evaluate the potential protective affects of Epo on left ventricular (LV) function and remodeling after acute myocardial infarction (MI).
Epo was injected into the peritoneum of male Wistar rats (250 g) during 6 weeks post induction of MI. Rats were divided into five groups: MI treated with single high dose (MT1, 5,000 U/kg, n=10), single high dose (5,000 U/kg) and repeated high doses (MTHi, 1,000 U/kg twice a week; n=8), or single high dose (5,000 U/kg) and repeated low doses (MTLo, 750 U/kg once a week, n=10), MI non-treated (MNT, n=10), sham (S, n=5). Echocardiography was performed 3.6+/-1.5 days and 43.7+/-2.3 days post MI. Collagen deposition and infarct size were measured on histological sections using computerized image analysis. Apoptosis was assessed by ApopTag staining.
Baseline fractional shortening (FS) was similar between groups. Six weeks after MI the FS of MTLo (26.9%) was significantly higher compared to MNT (17.8%), MT1 (19.5%) and MTH (22.3%) (p=0.01). However, remodeling indices (end diastolic and end systolic areas, LV circumference) did not improve in the Epo groups, and even worsened in the MTHi group. There was significantly less collagen staining in non-infarct areas in MT1 and MTHi groups compared to MNT and MTLo (0.38+/-0.3%, 0.49+/-0.34%, vs 0.89+/-0.41%, 0.95+/-0.33%, respectively, p<0.001). The number of ApopTag positive nucleus was significantly higher in the MNT group compared to the MT1, MTHi, MTLo groups (14.4+/-8, 7.6+/-4, 5.8+/-7, 4.8+/-5, respectively, p=0.01 for trend).
Repeated low doses of Epo after MI improved LV function, but the role of Epo on remodeling is not clear. It did not reduce left ventricular indices, but reduces fibrosis and apoptosis. High Epo doses reduced LV function and aggravated remodeling.</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/s10557-007-6049-8</identifier><identifier>PMID: 17912622</identifier><identifier>CODEN: CDTHET</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Acute Disease ; Animals ; Apoptosis - drug effects ; Biological and medical sciences ; C-Reactive Protein - analysis ; C-Reactive Protein - drug effects ; Cardiology. Vascular system ; Cardiovascular system ; Coronary heart disease ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Electrocardiography ; Erythropoietin - administration & dosage ; Heart ; Hemoglobins - analysis ; Male ; Medical sciences ; Myocardial Infarction - drug therapy ; Myocardial Infarction - pathology ; Myocardial Infarction - prevention & control ; Myocarditis. Cardiomyopathies ; Pharmacology. Drug treatments ; Rats ; Rats, Wistar ; Survival Rate ; Ventricular Function, Left - drug effects ; Ventricular Remodeling - drug effects</subject><ispartof>Cardiovascular drugs and therapy, 2007-10, Vol.21 (5), p.339-346</ispartof><rights>2008 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-b380be453417d52e3e25b801e4a542544e78a515514bbca441beb59b763ec1253</citedby><cites>FETCH-LOGICAL-c356t-b380be453417d52e3e25b801e4a542544e78a515514bbca441beb59b763ec1253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19221806$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17912622$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BEN-DOR, Itsik</creatorcontrib><creatorcontrib>HARDY, Britta</creatorcontrib><creatorcontrib>HARELL, Daniela</creatorcontrib><creatorcontrib>OKON, Elimelech</creatorcontrib><creatorcontrib>BATTLER, Alexander</creatorcontrib><creatorcontrib>HAIM, Moti</creatorcontrib><creatorcontrib>FUCHS, Shmuel</creatorcontrib><creatorcontrib>KAGANOVSKY, Ella</creatorcontrib><creatorcontrib>KADMON, Ehud</creatorcontrib><creatorcontrib>SAGIE, Alex</creatorcontrib><creatorcontrib>COLEMAN, Raymond</creatorcontrib><creatorcontrib>MANSUR, Mali</creatorcontrib><creatorcontrib>POLITI, Boaz</creatorcontrib><creatorcontrib>FRASER, Abigail</creatorcontrib><title>Repeated low-dose of erythropoietin is associated with improved left ventricular function in rat acute myocardial infarction model</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><description>To evaluate the potential protective affects of Epo on left ventricular (LV) function and remodeling after acute myocardial infarction (MI).
Epo was injected into the peritoneum of male Wistar rats (250 g) during 6 weeks post induction of MI. Rats were divided into five groups: MI treated with single high dose (MT1, 5,000 U/kg, n=10), single high dose (5,000 U/kg) and repeated high doses (MTHi, 1,000 U/kg twice a week; n=8), or single high dose (5,000 U/kg) and repeated low doses (MTLo, 750 U/kg once a week, n=10), MI non-treated (MNT, n=10), sham (S, n=5). Echocardiography was performed 3.6+/-1.5 days and 43.7+/-2.3 days post MI. Collagen deposition and infarct size were measured on histological sections using computerized image analysis. Apoptosis was assessed by ApopTag staining.
Baseline fractional shortening (FS) was similar between groups. Six weeks after MI the FS of MTLo (26.9%) was significantly higher compared to MNT (17.8%), MT1 (19.5%) and MTH (22.3%) (p=0.01). However, remodeling indices (end diastolic and end systolic areas, LV circumference) did not improve in the Epo groups, and even worsened in the MTHi group. There was significantly less collagen staining in non-infarct areas in MT1 and MTHi groups compared to MNT and MTLo (0.38+/-0.3%, 0.49+/-0.34%, vs 0.89+/-0.41%, 0.95+/-0.33%, respectively, p<0.001). The number of ApopTag positive nucleus was significantly higher in the MNT group compared to the MT1, MTHi, MTLo groups (14.4+/-8, 7.6+/-4, 5.8+/-7, 4.8+/-5, respectively, p=0.01 for trend).
Repeated low doses of Epo after MI improved LV function, but the role of Epo on remodeling is not clear. It did not reduce left ventricular indices, but reduces fibrosis and apoptosis. High Epo doses reduced LV function and aggravated remodeling.</description><subject>Acute Disease</subject><subject>Animals</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>C-Reactive Protein - analysis</subject><subject>C-Reactive Protein - drug effects</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular system</subject><subject>Coronary heart disease</subject><subject>Disease Models, Animal</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Electrocardiography</subject><subject>Erythropoietin - administration & dosage</subject><subject>Heart</subject><subject>Hemoglobins - analysis</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - pathology</subject><subject>Myocardial Infarction - prevention & control</subject><subject>Myocarditis. Cardiomyopathies</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Survival Rate</subject><subject>Ventricular Function, Left - drug effects</subject><subject>Ventricular Remodeling - drug effects</subject><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0cuKFDEUBuAgitOOPoAbCYLuorkntZRhvMCAILoOSeoUk6Gq0iapGXrrk5u2GwZc5RC-_3DgR-g1ox8YpeZjZVQpQ_pINJUDsU_QjikjiOGSPUU7OnBKBKf6Ar2o9Y52OAz2ObpgZmBcc75Df37AHnyDEc_5gYy5As4ThnJotyXvc4KWVpwq9rXmmP7Bh9RucVr2Jd8fYzA1fA9rKylusy942tbYUu6pFRffsI9bA7wccvRlTH7u_5MvJ7LkEeaX6Nnk5wqvzu8l-vX5-ufVV3Lz_cu3q083JAqlGwnC0gBSCcnMqDgI4CpYykB6JbmSEoz1iinFZAjRS8kCBDUEowVExpW4RO9Pe_vlvzeozS2pRphnv0LeqtNWSc2l6fDtf_Aub2XttznOhJWWad4RO6FYcq0FJrcvafHl4Bh1x3bcqR13HI_tONszb86Lt7DA-Jg419HBuzPwNfp5Kn6NqT66gXNmqRZ_ATfamTc</recordid><startdate>20071001</startdate><enddate>20071001</enddate><creator>BEN-DOR, Itsik</creator><creator>HARDY, Britta</creator><creator>HARELL, Daniela</creator><creator>OKON, Elimelech</creator><creator>BATTLER, Alexander</creator><creator>HAIM, Moti</creator><creator>FUCHS, Shmuel</creator><creator>KAGANOVSKY, Ella</creator><creator>KADMON, Ehud</creator><creator>SAGIE, Alex</creator><creator>COLEMAN, Raymond</creator><creator>MANSUR, Mali</creator><creator>POLITI, Boaz</creator><creator>FRASER, Abigail</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20071001</creationdate><title>Repeated low-dose of erythropoietin is associated with improved left ventricular function in rat acute myocardial infarction model</title><author>BEN-DOR, Itsik ; HARDY, Britta ; HARELL, Daniela ; OKON, Elimelech ; BATTLER, Alexander ; HAIM, Moti ; FUCHS, Shmuel ; KAGANOVSKY, Ella ; KADMON, Ehud ; SAGIE, Alex ; COLEMAN, Raymond ; MANSUR, Mali ; POLITI, Boaz ; FRASER, Abigail</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-b380be453417d52e3e25b801e4a542544e78a515514bbca441beb59b763ec1253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Acute Disease</topic><topic>Animals</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>C-Reactive Protein - analysis</topic><topic>C-Reactive Protein - drug effects</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular system</topic><topic>Coronary heart disease</topic><topic>Disease Models, Animal</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Electrocardiography</topic><topic>Erythropoietin - administration & dosage</topic><topic>Heart</topic><topic>Hemoglobins - analysis</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - pathology</topic><topic>Myocardial Infarction - prevention & control</topic><topic>Myocarditis. Cardiomyopathies</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Survival Rate</topic><topic>Ventricular Function, Left - drug effects</topic><topic>Ventricular Remodeling - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BEN-DOR, Itsik</creatorcontrib><creatorcontrib>HARDY, Britta</creatorcontrib><creatorcontrib>HARELL, Daniela</creatorcontrib><creatorcontrib>OKON, Elimelech</creatorcontrib><creatorcontrib>BATTLER, Alexander</creatorcontrib><creatorcontrib>HAIM, Moti</creatorcontrib><creatorcontrib>FUCHS, Shmuel</creatorcontrib><creatorcontrib>KAGANOVSKY, Ella</creatorcontrib><creatorcontrib>KADMON, Ehud</creatorcontrib><creatorcontrib>SAGIE, Alex</creatorcontrib><creatorcontrib>COLEMAN, Raymond</creatorcontrib><creatorcontrib>MANSUR, Mali</creatorcontrib><creatorcontrib>POLITI, Boaz</creatorcontrib><creatorcontrib>FRASER, Abigail</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BEN-DOR, Itsik</au><au>HARDY, Britta</au><au>HARELL, Daniela</au><au>OKON, Elimelech</au><au>BATTLER, Alexander</au><au>HAIM, Moti</au><au>FUCHS, Shmuel</au><au>KAGANOVSKY, Ella</au><au>KADMON, Ehud</au><au>SAGIE, Alex</au><au>COLEMAN, Raymond</au><au>MANSUR, Mali</au><au>POLITI, Boaz</au><au>FRASER, Abigail</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repeated low-dose of erythropoietin is associated with improved left ventricular function in rat acute myocardial infarction model</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>2007-10-01</date><risdate>2007</risdate><volume>21</volume><issue>5</issue><spage>339</spage><epage>346</epage><pages>339-346</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><coden>CDTHET</coden><abstract>To evaluate the potential protective affects of Epo on left ventricular (LV) function and remodeling after acute myocardial infarction (MI).
Epo was injected into the peritoneum of male Wistar rats (250 g) during 6 weeks post induction of MI. Rats were divided into five groups: MI treated with single high dose (MT1, 5,000 U/kg, n=10), single high dose (5,000 U/kg) and repeated high doses (MTHi, 1,000 U/kg twice a week; n=8), or single high dose (5,000 U/kg) and repeated low doses (MTLo, 750 U/kg once a week, n=10), MI non-treated (MNT, n=10), sham (S, n=5). Echocardiography was performed 3.6+/-1.5 days and 43.7+/-2.3 days post MI. Collagen deposition and infarct size were measured on histological sections using computerized image analysis. Apoptosis was assessed by ApopTag staining.
Baseline fractional shortening (FS) was similar between groups. Six weeks after MI the FS of MTLo (26.9%) was significantly higher compared to MNT (17.8%), MT1 (19.5%) and MTH (22.3%) (p=0.01). However, remodeling indices (end diastolic and end systolic areas, LV circumference) did not improve in the Epo groups, and even worsened in the MTHi group. There was significantly less collagen staining in non-infarct areas in MT1 and MTHi groups compared to MNT and MTLo (0.38+/-0.3%, 0.49+/-0.34%, vs 0.89+/-0.41%, 0.95+/-0.33%, respectively, p<0.001). The number of ApopTag positive nucleus was significantly higher in the MNT group compared to the MT1, MTHi, MTLo groups (14.4+/-8, 7.6+/-4, 5.8+/-7, 4.8+/-5, respectively, p=0.01 for trend).
Repeated low doses of Epo after MI improved LV function, but the role of Epo on remodeling is not clear. It did not reduce left ventricular indices, but reduces fibrosis and apoptosis. High Epo doses reduced LV function and aggravated remodeling.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>17912622</pmid><doi>10.1007/s10557-007-6049-8</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-3206 |
| ispartof | Cardiovascular drugs and therapy, 2007-10, Vol.21 (5), p.339-346 |
| issn | 0920-3206 1573-7241 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68546247 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Acute Disease Animals Apoptosis - drug effects Biological and medical sciences C-Reactive Protein - analysis C-Reactive Protein - drug effects Cardiology. Vascular system Cardiovascular system Coronary heart disease Disease Models, Animal Dose-Response Relationship, Drug Drug Administration Schedule Electrocardiography Erythropoietin - administration & dosage Heart Hemoglobins - analysis Male Medical sciences Myocardial Infarction - drug therapy Myocardial Infarction - pathology Myocardial Infarction - prevention & control Myocarditis. Cardiomyopathies Pharmacology. Drug treatments Rats Rats, Wistar Survival Rate Ventricular Function, Left - drug effects Ventricular Remodeling - drug effects |
| title | Repeated low-dose of erythropoietin is associated with improved left ventricular function in rat acute myocardial infarction model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A11%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repeated%20low-dose%20of%20erythropoietin%20is%20associated%20with%20improved%20left%20ventricular%20function%20in%20rat%20acute%20myocardial%20infarction%20model&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=BEN-DOR,%20Itsik&rft.date=2007-10-01&rft.volume=21&rft.issue=5&rft.spage=339&rft.epage=346&rft.pages=339-346&rft.issn=0920-3206&rft.eissn=1573-7241&rft.coden=CDTHET&rft_id=info:doi/10.1007/s10557-007-6049-8&rft_dat=%3Cproquest_cross%3E68546247%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213848162&rft_id=info:pmid/17912622&rfr_iscdi=true |